Price range: £138.08 through £164.48

SKU ACEEPIAMI Category

Acetyl Epitalon is an Acetyl Epitalon peptide designed as a stabilized analogue of Epitalon. Researchers use this tetrapeptide to study cellular aging mechanisms, telomeric regulation, and pineal-peptide signaling in controlled scientific environments. Because acetylation enhances the peptide’s structural stability and resistance to degradation, the Acetyl Epitalon peptide supports studies that require reliable long-duration activity.

Scientists value the Acetyl Epitalon peptide for its relevance in experiments focused on genomic protection, oxidative-stress responses, and regulatory processes linked to cell longevity. It enables researchers to explore how modified pineal peptides may influence gene-expression dynamics and cellular maintenance pathways under defined laboratory conditions. Additionally, Acetyl Epitalon provides a direct comparison point to unmodified Epitalon, helping investigators evaluate structure–activity enhancements.

Research teams often choose the Acetyl Epitalon peptide for:

  • Mapping telomere-associated biochemical signaling

  • Studying aging-related regulatory pathways in vitro

  • Analysing oxidative and metabolic stability effects

  • Comparing performance between acetylated and non-acetylated analogues

Because Acetyl Epitalon exhibits consistent behavior in controlled systems, it supports reproducible data collection and precise mechanistic studies. Its stability makes it suitable for extended cell-culture assays and aging-pathway evaluations requiring clean, traceable exposure patterns.

Our Acetyl Epitalon peptide is supplied as a high-purity laboratory reagent intended only for qualified scientific professionals. It is not approved for clinical, therapeutic, diagnostic, or veterinary use. All handling must comply with institutional safety and regulatory protocols for investigational compounds.

For research use only. Not for human consumption.

COA Request

GET 10% OFF

Recieve product and research updates through our newsletter